ClinicalTrials.gg
Not yet recruitingNCT05976568Updated Aug 4, 2023

A Study of QL1706 in Combination With Bevacizumab and/or Chemotherapy as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma

A Phase 2/3 interventional study of QL1706 and Bevacizumab in Hepatocellular Carcinoma, sponsored by Qilu Pharmaceutical Co., Ltd.. Not yet recruiting at 2 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-08-04.

Sponsored by Qilu Pharmaceutical Co., Ltd. · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
668
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies testing Iparomlimab/Tuvonralimab in Carcinoma, Hepatocellular — 14 open to participants now, 14 under way, 1 of them phase 3. Iparomlimab/Tuvonralimab · Carcinoma, Hepatocellular.

Planned enrollment
Largest of 14
668 · median 36
Started
2023
the only one that year
Phase 2/3
Only one
of the 14
Primary completion
2027-09
later than 5 of 13 live
Registered
1st of 14
by date
Lead sponsor
1 of 14
Qilu Pharmaceutical Co., Ltd.

Among the 14 studies testing Iparomlimab/Tuvonralimab in Carcinoma, Hepatocellular, this one has the largest planned enrollment, is the only one that started in 2023, is the only one in phase 2/3, reaches primary completion later than 5 of the 13 other live ones, and was the 1st registered.

Carcinoma, Hepatocellular

3,651 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,063 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

14 of the 14 studies testing Iparomlimab/Tuvonralimab in Carcinoma, Hepatocellular are open now, in 1 country. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 14 open studies →

Where they have run

About Iparomlimab/Tuvonralimab

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 739 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 249 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing Iparomlimab/Tuvonralimab in Carcinoma, Hepatocellular, or all of them as a file.
02

Study summary

The purpose of this study is to assess the efficacy and safety of QL1706 in combination with bevacizumab and/or chemotherapy versus sintilimab in combination with bevacizumab as first-line treatment in patients with advanced hepatocellular carcinoma.

03

Conditions studied

  • Hepatocellular Carcinoma
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects participate voluntarily and sign .
  2. Age ≥ 18 and ≤ 80 years old, male or female.
  3. Histological or cytological or clinical diagnosis of HCC
  4. Barcelona Clinic Liver Cancer stage C. BCLC stage B, not suitable for radical surgery and/or local treatment.
  5. No prior systemic therapy for HCC.
  6. ≤7 , no history of hepatic encephalopathy.

Exclusion criteria

Exclusion Criteria:

  1. or cytologically documented fibrolamellar hepatocellular carcinoma, sarcoma-like hepatocellular carcinoma, cholangiocarcinoma, etc.
  2. History of other than HCC within 5 years prior to the start of study treatment.
  3. History of liver transplantation, or planned to receive liver transplantation.
  4. Moderate or severe ascites with clinical symptoms that require drainage, uncontrolled or moderate or severe pleural and pericardical effusion.
  5. Has known active central nervous system (CNS) and/or carcinomatous meningitis.
  6. Involvement of both the main portal vein and the left and right branches by portal vein tumor thrombus, or of both the main trunk and the superior mesenteric vein concurrently, or of inferior vena cava.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
668 participants (estimated)

Study arms

  • Experimental
    Arm 1

    QL1706 in combination with bevacizumab and chemotherapy

    Drug: QL1706 · Drug: Bevacizumab · Drug: Oxaliplatin injection · Drug: Capecitabine

  • Experimental
    Arm 2

    QL1706 in combination with bevacizumab

    Drug: QL1706 · Drug: Bevacizumab

  • Experimental
    Arm 3

    QL1706 in combination with chemotherapy

    Drug: QL1706 · Drug: Oxaliplatin injection · Drug: Capecitabine

  • Active comparator
    Arm 4

    Sintilimab in combination with bevacizumab

    Drug: Bevacizumab · Drug: Sintilimab

Interventions

  • DrugQL1706

    7.5 mg/kg administered as IV infusion on Day 1 of each 21-day cycle

  • 15 mg/kg administered as IV infusion on Day 1 of each 21-day cycle

  • 85 mg/m2 administered as IV infusion on Day 1 of each 21-day cycle

  • 1000 mg/m2 orally twice daily for 14 days continuous dosing followed by a 7-day break of each 21-day cycle

  • 200 mg administered as IV infusion on Day 1 of each 21-day cycle

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR) (Phase II)

    ORR was assessed by investigators per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1).

    Time frame: Up to approximately 4 years

  2. Incidence of Adverse Events (AEs) (Phase II)

    An adverse event is any untoward medical occurrence in a subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product.

    Time frame: Up to approximately 4 years

  3. Overall Survival (OS) (Phase III)

    OS was defined as the time from randomization to death due to any cause.

    Time frame: Up to approximately 4 years

Secondary outcomes

  1. Objective Response Rate (ORR)

    ORR was assessed by investigators per RECIST 1.1

    Time frame: Up to approximately 4 years

  2. Disease Control Rate (DCR)

    DCR was assessed by investigators per RECIST 1.1

    Time frame: Up to approximately 4 years

  3. Duration of Response (DOR)

    DOR was assessed by investigators per RECIST 1.1

    Time frame: Up to approximately 4 years

  4. Progression-free Survival (PFS)

    PFS was assessed by investigators per RECIST 1.1

    Time frame: Up to approximately 4 years

  5. Time to progression (TTP)

    TTP was assessed by investigators per RECIST 1.1

    Time frame: Up to approximately 4 years

  6. Objective Response Rate (ORR)

    ORR was assessed by investigators per mRECIST

    Time frame: Up to approximately 4 years

  7. Disease Control Rate (DCR)

    DCR was assessed by investigators per mRECIST

    Time frame: Up to approximately 4 years

  8. Duration of Response (DOR)

    DOR was assessed by investigators per mRECIST

    Time frame: Up to approximately 4 years

  9. Progression-free Survival (PFS)

    PFS was assessed by investigators per mRECIST

    Time frame: Up to approximately 4 years

  10. Time to progression (TTP)

    TTP was assessed by investigators per mRECIST

    Time frame: Up to approximately 4 years

07

Study locations

2 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Sep 2023; primary completion for Sep 2027, 48 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 28, 2023
First posted
Aug 4, 2023
StartEst.
Sep 1, 2023
Primary completionEst.
Sep 1, 2027
CompletionEst.
Sep 1, 2027
Last update
Aug 4, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 4, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05976568
Responsible party
Sponsor
First posted
Aug 4, 2023
Start date
Sep 1, 2023 (estimated)
Primary completion
Sep 1, 2027 (estimated)
Completion
Sep 1, 2027 (estimated)
Last update
Aug 4, 2023

Study contacts

Jian Gao
Contact
jian7.gao@qilu-pharma.com
+8613304321400
Jia Fan
principal investigator · Fudan University
Shukui Qin
principal investigator · Nanjing Tianyinshan Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Iparomlimab/Tuvonralimab · Bevacizumab

Start the discussion